SK Biopharmaceuticals Co., Ltd.
326030
Ранг среди акций
#3730
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Цена акции
$56.51
Рыночная капитализация
$4.43B
Изменение (1 день)
0.00%
Изменение (1 год)
-25.24%
Страна
KR
Торговля SK Biopharmaceuticals Co., Ltd. (326030)
Категория
Healthcare
История цены акций SK Biopharmaceuticals Co., Ltd. (326030)
Наивысшая цена закрытия: $51.70 2026-10-01
Наименьшая цена закрытия: $157.85 2020-07-01
Наименьшая цена закрытия: $157.85 2020-07-01
История цены акций SK Biopharmaceuticals Co., Ltd. с 2020 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | -22.47% |
| 2025 | 24.61% |
| 2024 | 2.56% |
| 2023 | 25.24% |
| 2022 | -33.05% |
| 2021 | -47.19% |
| 2020 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $536.87 | 25.89% |
US
|
|
| $191.60 | 613.60% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $884.30 | 8.61% |
NL
|
